Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

ClinicalTrials.gov ID: NCT02139644

Public ClinicalTrials.gov record NCT02139644. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Low-dose or or Mid-dose Inhaled Corticosteroid Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when administered over 12 weeks in patients 12 years of age and older with persistent asthma. Study drug and placebo was supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants performed spirometry at every visit. Each participant was given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) was dispensed at each visit, if needed, as determined by the investigational center personnel.

Study identification

NCT ID
NCT02139644
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
787 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2014
Primary completion
Aug 31, 2015
Completion
Aug 31, 2015
Last update posted
Nov 11, 2021

2014 – 2015

United States locations

U.S. sites
76
U.S. states
27
U.S. cities
67
Facility City State ZIP Site status
Teva Investigational Site 12397 Birmingham Alabama
Teva Investigational Site 12375 Glendale Arizona
Teva Investigational Site 12395 Cypress California
Teva Investigational Site 12476 Encinitas California
Teva Investigational Site 12586 Fountain Valley California
Teva Investigational Site 12591 Fresno California
Teva Investigational Site 12372 Huntington Beach California
Teva Investigational Site 12365 Los Angeles California
Teva Investigational Site 12381 Los Angeles California
Teva Investigational Site 12401 Los Angeles California
Teva Investigational Site 12394 Mission Viejo California
Teva Investigational Site 12490 Rancho Mirage California
Teva Investigational Site 12393 Riverside California
Teva Investigational Site 12366 Rolling Hills Estates California
Teva Investigational Site 12383 San Diego California
Teva Investigational Site 12370 San Jose California
Teva Investigational Site 12371 Stockton California
Teva Investigational Site 12579 Upland California
Teva Investigational Site 12379 Centennial Colorado
Teva Investigational Site 12386 Centennial Colorado
Teva Investigational Site 12596 Colorado Springs Colorado
Teva Investigational Site 12584 Longmont Colorado
Teva Investigational Site 12484 Waterbury Connecticut
Teva Investigational Site 12590 Waterbury Connecticut
Teva Investigational Site 12493 Clearwater Florida
Teva Investigational Site 12992 Largo Florida
Teva Investigational Site 12376 Miami Florida
Teva Investigational Site 12390 Miami Florida
Teva Investigational Site 12583 Orlando Florida
Teva Investigational Site 12481 Tallahassee Florida
Teva Investigational Site 12491 Winter Park Florida
Teva Investigational Site 12997 Decatur Georgia
Teva Investigational Site 12392 Savannah Georgia
Teva Investigational Site 12592 Shiloh Illinois
Teva Investigational Site 12483 Lenexa Kansas
Teva Investigational Site 12399 Baltimore Maryland
Teva Investigational Site 12391 Bethesda Maryland
Teva Investigational Site 12589 Columbia Maryland
Teva Investigational Site 12369 Rockville Maryland
Teva Investigational Site 12396 Fall River Massachusetts
Teva Investigational Site 12384 North Dartmouth Massachusetts
Teva Investigational Site 12585 North Dartmouth Massachusetts
Teva Investigational Site 12588 Ypsilanti Michigan
Teva Investigational Site 12494 St Louis Missouri
Teva Investigational Site 12595 St Louis Missouri
Teva Investigational Site 12594 Missoula Montana
Teva Investigational Site 12385 Ocean City New Jersey
Teva Investigational Site 12380 Skillman New Jersey
Teva Investigational Site 12587 Brooklyn New York
Teva Investigational Site 12485 Rockville Centre New York
Teva Investigational Site 12475 Huntersville North Carolina
Teva Investigational Site 12364 Raleigh North Carolina
Teva Investigational Site 12374 Canton Ohio
Teva Investigational Site 12480 Cincinnati Ohio
Teva Investigational Site 12492 Cincinnati Ohio
Teva Investigational Site 12487 Middleburg Heights Ohio
Teva Investigational Site 12488 Sylvania Ohio
Teva Investigational Site 12377 Edmond Oklahoma
Teva Investigational Site 12368 Medford Oregon
Teva Investigational Site 12382 Portland Oregon
Teva Investigational Site 12400 Pittsburgh Pennsylvania
Teva Investigational Site 12473 Upland Pennsylvania
Teva Investigational Site 12389 Greenville South Carolina
Teva Investigational Site 12580 Mt. Pleasant South Carolina
Teva Investigational Site 12398 Orangeburg South Carolina
Teva Investigational Site 12991 Knoxville Tennessee
Teva Investigational Site 12990 Cypress Texas
Teva Investigational Site 12373 Dallas Texas
Teva Investigational Site 12402 El Paso Texas
Teva Investigational Site 12582 New Braunfels Texas
Teva Investigational Site 12363 San Antonio Texas
Teva Investigational Site 12482 San Antonio Texas
Teva Investigational Site 12477 Waco Texas
Teva Investigational Site 12478 Murray Utah
Teva Investigational Site 12388 South Burlington Vermont
Teva Investigational Site 12378 Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02139644, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 11, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02139644 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →